ZAMPINO, Rosa
 Distribuzione geografica
Continente #
NA - Nord America 4.444
EU - Europa 4.354
AS - Asia 590
Continente sconosciuto - Info sul continente non disponibili 12
SA - Sud America 8
AF - Africa 4
OC - Oceania 1
Totale 9.413
Nazione #
US - Stati Uniti d'America 4.417
IE - Irlanda 1.572
UA - Ucraina 788
GB - Regno Unito 613
CN - Cina 381
DE - Germania 333
IT - Italia 326
SE - Svezia 247
FI - Finlandia 206
TR - Turchia 174
GR - Grecia 154
FR - Francia 70
BE - Belgio 17
CA - Canada 16
EU - Europa 12
MX - Messico 11
SG - Singapore 10
IN - India 7
NL - Olanda 7
RU - Federazione Russa 7
IR - Iran 6
SA - Arabia Saudita 4
AR - Argentina 3
CO - Colombia 3
ES - Italia 3
JP - Giappone 3
PL - Polonia 2
BR - Brasile 1
BW - Botswana 1
CH - Svizzera 1
CL - Cile 1
EG - Egitto 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
IL - Israele 1
LI - Liechtenstein 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
TN - Tunisia 1
VN - Vietnam 1
Totale 9.413
Città #
Dublin 1.571
Jacksonville 1.197
Chandler 724
Princeton 243
Roxbury 195
New York 167
Ann Arbor 143
Cambridge 142
Woodbridge 121
Boardman 117
Bremen 110
Wilmington 108
Medford 105
Beijing 59
San Mateo 55
Jinan 54
Ashburn 53
Des Moines 52
Mountain View 50
Nanjing 48
Düsseldorf 45
Shenyang 40
Norwalk 28
Napoli 27
Caserta 25
Washington 20
Brussels 17
Helsinki 17
Zhengzhou 17
Changsha 16
Houston 15
Lanzhou 14
Marano Di Napoli 14
Ningbo 13
Haikou 12
Taizhou 12
Tianjin 12
Guangzhou 11
Hebei 11
Nanchang 11
Auburn Hills 10
Guadalupe 10
Rome 9
Bologna 8
Hangzhou 8
Seattle 8
Venice 8
Volvera 8
Los Angeles 7
Naples 7
Ottawa 7
Athens 6
Bari 6
Dearborn 6
Fairfield 6
Kunming 6
Latisana 6
Changchun 5
Taiyuan 5
Toronto 5
Zanjan 5
Elora 4
Groningen 4
Jiaxing 4
Menlo Park 4
Quarto 4
Rossano 4
Duncan 3
Hefei 3
Milan 3
Moscow 3
Munich 3
Orange 3
Perugia 3
Philadelphia 3
San Francisco 3
Singapore 3
Torino 3
Amsterdam 2
Atripalda 2
Berlin 2
Boydton 2
Brindisi 2
Elice 2
Florence 2
Lappeenranta 2
Malo 2
Marano 2
Padova 2
Palermo 2
Pistoia 2
Pomigliano D'arco 2
Saint Paul 2
Salerno 2
Shanghai 2
Tokyo 2
Torre Del Greco 2
Villa Literno 2
Alghero 1
Altofonte 1
Totale 5.936
Nome #
Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration 89
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms 81
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C 77
Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. 75
Ruolo eziologico e patogenetico del virus dell'epatite C (HCV) nella crioglobulinemia mista (CM) in pazienti con epatite cronica (EC). 73
null 71
Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment 71
Nocardiosi polmonare in pazienti con trapianto di cuore: casi clinici 70
Chronic HCV Infection is risk of atherosclerosis. Role of HCV and HCV-related steatosis 68
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe. 67
The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. 66
Chronic HCV infection and neurological and psychiatric disorders: an overview. 63
PNPLA3 l148M variant as a risk factor for carotid atherosclerosis in chronic epatiti C 63
HCV RNA levels in serum, liver and PBMC of chronic hepatitis C patients: pathological and therapeutic significance. 63
Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B 61
ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens. 61
Decrease in HDV endemicity in Italy 60
Esperienza con l'interferone linfoblastoide nelle epatiti croniche virali 59
Celiachia silente in pazienti con epatite C: prevalenza, effetto del trattamento con alfa-interferone sull’attivazione della malattia ed evoluzione clinica 59
Long term effect of interferon (IFN) treatment of chronic hepatitis B (CHB) in pediatric patients cured of oncologic diseases 59
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection 58
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B. 58
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon 57
Cannabinoid Receptor 2 (CB2) Q63 variant in chronic hepatitis C: an association with a more severe hepatocellular necrosis. 57
Disordini immunologici in corso di epatite cronica da HCV: prevalenza significato clinico ed implicazioni terapeutiche. 57
Aspetti clinico terapeutici della crioglobulinemia mista associata all’epatite cronica C: esperienza su un ampia casistica. 57
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 57
Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B 57
Interferon-induced anti-HBE seroconversion correlates with a Th1 cytokine shift following emergence of core promoter mutations in chronic hepatitis B 56
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore. 56
Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study 55
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe 55
Cannabinoid receptor 2 (CB2) Q63 variant is associated with a severe histological activity index in patients with chronic hepatitis C 55
Different serological, molecular and cytokine profiles characterize active and inactive disease in patients with chronic hepatitis B virus (HBV) infection 55
Effects of long-term alfa interferon treatment in 344 patients with chronic hepatitis C: retrospective analysis of dosage and type of interferon used 54
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B 54
L'endocardite da Enterococco: nostra esperienza nel periodo 1988-93. 54
CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. 54
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 54
Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission 53
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 53
Infezioni polmonari micotiche e da nocardia nel paziente cardiotrapiantato: caratteristiche cliniche e trattamento 53
Comunicazione orale: Cinetica precoce dell’HCV-RNA in pazienti con epatite cronica: correlati clinico-virologici e valore predittivo la risposta al trattamento antivirale 53
EFFICACIA DEL TRATTAMENTO CON INTERFERONE RICOMBINANTE E LINFOBLASTOIDE IN PAZIENTI CON EPATITE CRONICA DA HCV 53
Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C 52
Effective itraconazole treatment of pulmonary aspergillosis in heart transplant patients 52
Polimorfismo di IL28B nei soggetti con infezione cronica da HCV con transaminasi persistentemente normali e nei pazienti con epatite cronica d HCV 52
Interferon plus lamivudine treatment in young patients with chronic active B and C hepatitis 52
Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study 51
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. 51
Mild chronic hepatitis C with steatosis: Which treatment? 51
Chronic hepatitis B infection in pediatric patients cured of oncologic diseases: natural history and effect of interferon treatment 51
Correlation of serum HBeAg levels and double A1762T/G1764A HBV core promoter mutation with response to interferon in patients with chronic hepatitis B 51
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis 50
Le infezioni delle basse vie urinarie: eziologia e suscettibilità agli antibiotici. Nostra esperienza negli ultimi 4 anni. 50
Ruolo patogenetico dell’adiponectina nella steatosi associata ad epatite C 50
Meningite batterica: epidemiologia e problematiche attuali di terapia. 50
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. 50
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients 49
HCV-related steatosis and risk of atherosclerosis 49
La epatite cronica da HCV con steatosi si associa ad elevato rischio aterosclerotico. 49
Efficacia del trattamento con interferone ricombinante e linfoblastoide in pazienti con epatite cronica da HCV. 49
Treatment of chronic HBV infection in developing countries. 49
Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment 48
Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays 48
Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays 48
SEQUENTIAL ANALYSIS OF HEPATITIS B VIRUS CORE PROMOTER AND PRECORE REGIONS IN CANCER SURVIVOR PATIENTS WITH CHRONIC HEPATITIS B BEFORE, DURING AND AFTER INTERFERON TREATMENT 48
Tm6sf2 e167k variant is associated with severe steatosis in chronic hepatitis c, regardless of pnapl3 polymorphism 48
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore 48
Infezioni respiratorie da Branhamella Catarralis in pazienti sottoposti a trapianto di cuore 48
ESPERIENZA CON L'INTERFERONE LINFOBLASTOIDE NELLE EPATITI CRONICHE VIRALI 48
Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant 48
Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients 47
Hepatitis G virus/GBV-C persistence: absence of hypervariable E2 region and genetic analysis of viral quasispecies in serum and lymphocytes 47
ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population 47
Aspetti diagnostici di mutanti della regione HBsAg in pazienti immunocompromessi con riattivazione dell’infezione da virus dell’epatite B (HBV). 47
Comunicazione orale: Embolia maggiore nell’endocardite infettiva: associazione con l’età e la risposta di fase acuta 47
First-phase HCV-RNA kinetic during antiviral therapy for chronic hepatitis C: clinical and virological correlates and predictive value for treatment outcome 47
The TM6SFZ 8167K variant is an independent predictor of severe liver steatosis in chronic hepatitis C 47
Intra-familial transmission of hepatitis B virus in Italy: phylogenetic sequence analysis and amino-acid variation of the core gene 46
Embolia maggiore nell’endocardite infettiva: associazione con l’età e la risposta di fase acuta 46
Colestasi intraepatica in pazienti sottoposti a trapianto di cuore 46
Correlazione tra livelli di HCV-RNA nel siero, nel fegato e nei linfo-monociti del sangue periferico: possibile ruolo predittivo di risposta all'interferone. 46
La presenza della variante Q63 del recettore dei cannabinoidi (CB2) si associa ad un più severa epatonecrosi nei pazienti con epatite cronica C. 46
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. 46
Virological patterns of HCV patients with failure to interferon-free regimens. 46
No effect of MTP polymorphisms on PNPLA3 in HCV-correlated steatosis 46
Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection 45
Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection 45
A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon 45
Comunicazione orale: Correlates and predictive value of early HCV-RNA kinetic during antiviral treatment 45
Comparison of dual HBV-HCV versus single HBV or HCV infections in a previous oncologic pediatric population. 44
Correlation between hepatitis C virus RNA levels in serum, liver, peripheral blood mononuclear cells and severity of liver disease in chronic hepatitis C patients. apitolo 27, pag. 244-250, 1996. 44
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. 44
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: An open-label, randomised controlled trial 44
Le infezioni delle basse vie urinarie: eziologia e suscettibilità agli antibiotici.Nostra esperienza negli ultimi 4 anni. 43
La combinazione interferone (IFN) con N-acetil cisteina o IFN con ofloxacina non migliora la risposta in pazienti con CHC non responders al solo IFN: Studio di fase I. 43
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosi 43
Long-term outcome of HBV-HCV co-infection and HBV mono-infection acquired in youth 42
Evidence for MCH class II-mediated immune selection pressure in HBV pre-core/core sequences 42
Totale 5.337
Categoria #
all - tutte 36.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.832


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201936 0 0 0 0 0 0 0 0 0 0 24 12
2019/20201.095 238 214 12 6 202 24 245 34 53 22 38 7
2020/20211.780 128 4 192 105 412 7 227 183 13 233 202 74
2021/20221.446 58 13 4 14 482 19 26 44 63 149 110 464
2022/20232.945 261 50 33 228 339 227 10 168 1.486 25 56 62
2023/2024926 94 28 41 72 421 181 34 36 6 13 0 0
Totale 9.824